Abstract:Abstract Background Novartis and the University of Oxford’s Big Data Institute (BDI) have established a research alliance with the aim to improve health care and drug development by making it more efficient and targeted. Using a combination of the latest statistical machine learning technology with an innovative IT platform developed to manage large volumes of anonymised data from numerous data sources and types we plan to identify novel patterns with clinical relevance which cannot be detected by humans alone to identify phenotypes and early predictors of patient disease activity and progression. Method The collaboration focuses on highly complex autoimmune diseases and develops a computational framework to assemble a research-ready dataset across numerous modalities. For the Multiple Sclerosis (MS) project, the collaboration has anonymised and integrated phase II to phase IV clinical and imaging trial data from ≈35,000 patients across all clinical phenotypes and collected in more than 2200 centres worldwide. For the “IL-17” project, the collaboration has anonymised and integrated clinical and imaging data from over 30 phase II and III Cosentyx clinical trials including more than 15,000 patients, suffering from four autoimmune disorders (Psoriasis, Axial Spondyloarthritis, Psoriatic arthritis (PsA) and Rheumatoid arthritis (RA)). Results A fundamental component of successful data analysis and the collaborative development of novel machine learning methods on these rich data sets has been the construction of a research informatics framework that can capture the data at regular intervals where images could be anonymised and integrated with the de-identified clinical data, quality controlled and compiled into a research-ready relational database which would then be available to multi-disciplinary analysts. The collaborative development from a group of software developers, data wranglers, statisticians, clinicians, and domain scientists across both organisations has been key. This framework is innovative, as it facilitates collaborative data management and makes a complicated clinical trial data set from a pharmaceutical company available to academic researchers who become associated with the project. Conclusions An informatics framework has been developed to capture clinical trial data into a pipeline of anonymisation, quality control, data exploration, and subsequent integration into a database. Establishing this framework has been integral to the development of analytical tools.

A case study of visualization to assess the progress of drug discovery research projects in academia: the possibility of building a support system based on common milestones for facilitating collaboration with industry

The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development

CollaborationViz: Interactive Visual Exploration of Biomedical Research Collaboration Networks

The Use of Web Ontology Languages and Other Semantic Web Tools in Drug Discovery.

Importance of scientific collaboration in contemporary drug discovery and development: a detailed network analysis

[A capability to promote the utilization of human samples for improving the ‍clinical response predictability in the pharmaceutical company]

Dydruma : A Dynamic Drug Map for Exploring the Associations Among Drug Therapeutic Indications and Side-Effects

Data-intensive drug development in the information age: applications of Systems Biology/Pharmacology/Toxicology

A data science roadmap for open science organizations engaged in early-stage drug discovery

DRAP: a Toolbox for Drug Response Analysis and Visualization Tailored for Preclinical Drug Testing on Patient-Derived Xenograft Models

Drugst.One -- A plug-and-play solution for online systems medicine and network-based drug repurposing

Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis

Visualizing and Analyzing the Chemical Space of Natural Product Databases for Drug Discovery

Strategic partnerships for AI-driven drug discovery: The role of relational dynamics

Bridging Islands of Information to Establish an Integrated Knowledge Base of Drugs and Health Outcomes of Interest

Academic drug discovery: Challenges and opportunities

Model-Adaptive Interface Generation for Data-Driven Discovery

The Application of the Open Pharmacological Concepts Triple Store (Open PHACTS) to Support Drug Discovery Research

Navigating the oncology drug discovery and development process with programmes supported by the National Institutes of Health

CytoCopasi: a chemical systems biology target and drug discovery visual data analytics platform

A Discussion about the Spread of “ Industry Academia Collaboration ” in Japan Based on the Text Mining Analysis of Newspaper Articles